# Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea

> **NCT01215669** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 240 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** IDflu™: Split virion inactivated influenza vaccine
- **BIOLOGICAL:** Vaxigrip®: Split virion inactivated influenza vaccine
- **BIOLOGICAL:** IDflu™: Split virion inactivated influenza vaccine
- **BIOLOGICAL:** Vaxigrip®: Split virion inactivated influenza vaccine

## Key facts

- **NCT ID:** NCT01215669
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-02
- **Final completion:** 2011-04
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215669, "Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01215669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*